295 Predictive genetic biomarkers for the development of peritoneal metastases in colorectal cancer SUPPLEMENTARY The following supplementary material can be downloaded from: • Figure S1. Details patient selection and data analysis • Figure S2. Boxplots of median unstable MSI sites (%) and median TMB • Figure S3. Overview of genes included in the TruSight Oncology 500 panel. [Illumina, Inc. (n.d.)] • Table S1. Overview of tumor sample characteristics • Table S2. (1) Overview of DNA sequencing (likely) pathogenic variant types and amplifications of total cohort (2) Overview of DNA sequencing (likely) pathogenic variant types and amplifications after MSI samples exclusion • Table S3. Detailed overview of (likely) pathogenic DNA mutations and amplifications Supplementary Section S2: Analysis on total cohort (MSI + MSS samples) • Table S4. Detailed overview percentage of mutated/amplified gene in each subgroup after MSI sample deletion, with statistical analysis • Figure S4. Oncoplot of variants across samples. Genes on y-axis, samples on x-axis • Figure S5. (A) Distribution of well-known oncogenes related to CRC between subgroups. (B) Genes mutated or amplified* in PM group only. (C) Genes mutated or amplified* in LM group only. (D) Genes mutated in LM and PM group (not in M0) • Table S5. Detailed overview percentage of mutated/amplified gene in each subgroup with statistical analysis 12
RkJQdWJsaXNoZXIy MTk4NDMw